Olaparib maintenance (HRD+ ovarian post-platinum response)

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.

Source YAML: complete record

Components	`DRUG-OLAPARIB`

ID	`REG-OLAPARIB-MAINT-OVARIAN`
Type	Regimen
Status	reviewed 2026-04-26 \| pending_clinical_signoff
Diseases	None declared
Sources	`SRC-ESMO-OVARIAN-2024` `SRC-NCCN-OVARIAN-2025`

Notes

SOLO-1 (BRCA-mut maintenance after platinum 1L response): mPFS 56 vs 14 mo (4× improvement). 5-yr OS interim: ~67% vs 47%. PAOLA-1 (bev + olaparib in HRD+): mPFS 37 vs 22 mo. Long-term MDS/AML risk warrants pre-treatment counseling.

Used By

Handbook Chapters

HB-OVARIAN-MAINTENANCE-1L - Advanced ovarian cancer: HRD/BRCA first-line maintenance reasoning

Handbook Questions

HQ-OVARIAN-MAINTENANCE-1L-001 - HQ-OVARIAN-MAINTENANCE-1L-001

Indication

IND-OVARIAN-MAINT-PARPI-BRCAM-OLAPARIB - IND-OVARIAN-MAINT-PARPI-BRCAM-OLAPARIB
IND-OVARIAN-MAINTENANCE-OLAPARIB - IND-OVARIAN-MAINTENANCE-OLAPARIB

Regimen

REG-RUCAPARIB-MAINT-OVARIAN - Rucaparib maintenance (recurrent platinum-sensitive ovarian, ARIEL3)